Factors associated with feelings of loss of masculinity in men with prostate cancer in the RADAR trial

Christopher F. Sharpley, Vicki Bitsika, James W. Denham

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Abstract

Objectives To identify the factors underlying prostate cancer (PCa) patients' depression-anxiety, sexual problems, urinary dysfunction and androgen deprivation therapy (ADT)-linked breast changes and hot flushes, and test these as predictors of loss of masculinity (LoM) over 36months following diagnosis. Methods One thousand seventy patients from the TROG 03.04 (RADAR) trial the EORTC QLQ C-30 and PR 25 questionnaires, and the International Prostate Cancer Symptom Score of the American Urological Association at baseline, 3, 7, 12, 18, 24 and 36months. Selected items from these scales were factor-analysed to identify a four-component solution for responses at 18 and 36months, and these components were regressed against a single-item measuring LoM. Results Depression-anxiety factor was the most powerful predictor of LoM at both time points, followed by sexual problems of ADT side effects (breast changes and hot flushes). Urinary dysfunction was not a consistent predictor of LoM. Depression-anxiety was also the most significant factor distinguishing between those men who reported LoM and those who did not. Conclusions Although LoM is often reported as arising from ADT, the relative power of depression-anxiety in predicting LoM, both at the selected time points and using a time-lagged analysis, plus the finding that depression-anxiety was the most consistent difference between men who reported LoM and those who did not, argues for the presence of adverse mood states as being the key ingredient in deciding if PCa patients experience loss of their feelings of masculinity.

Original languageEnglish
Pages (from-to)524-530
Number of pages7
JournalPsycho-Oncology
Volume23
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Masculinity
Prostatic Neoplasms
Emotions
Anxiety
Depression
Androgens
Breast
Therapeutics

Cite this

Sharpley, Christopher F. ; Bitsika, Vicki ; Denham, James W. / Factors associated with feelings of loss of masculinity in men with prostate cancer in the RADAR trial. In: Psycho-Oncology. 2014 ; Vol. 23, No. 5. pp. 524-530.
@article{40a633dd5b1b4d3f80db478f60773536,
title = "Factors associated with feelings of loss of masculinity in men with prostate cancer in the RADAR trial",
abstract = "Objectives To identify the factors underlying prostate cancer (PCa) patients' depression-anxiety, sexual problems, urinary dysfunction and androgen deprivation therapy (ADT)-linked breast changes and hot flushes, and test these as predictors of loss of masculinity (LoM) over 36months following diagnosis. Methods One thousand seventy patients from the TROG 03.04 (RADAR) trial the EORTC QLQ C-30 and PR 25 questionnaires, and the International Prostate Cancer Symptom Score of the American Urological Association at baseline, 3, 7, 12, 18, 24 and 36months. Selected items from these scales were factor-analysed to identify a four-component solution for responses at 18 and 36months, and these components were regressed against a single-item measuring LoM. Results Depression-anxiety factor was the most powerful predictor of LoM at both time points, followed by sexual problems of ADT side effects (breast changes and hot flushes). Urinary dysfunction was not a consistent predictor of LoM. Depression-anxiety was also the most significant factor distinguishing between those men who reported LoM and those who did not. Conclusions Although LoM is often reported as arising from ADT, the relative power of depression-anxiety in predicting LoM, both at the selected time points and using a time-lagged analysis, plus the finding that depression-anxiety was the most consistent difference between men who reported LoM and those who did not, argues for the presence of adverse mood states as being the key ingredient in deciding if PCa patients experience loss of their feelings of masculinity.",
author = "Sharpley, {Christopher F.} and Vicki Bitsika and Denham, {James W.}",
year = "2014",
doi = "10.1002/pon.3448",
language = "English",
volume = "23",
pages = "524--530",
journal = "Psycho-Oncology",
issn = "1057-9249",
publisher = "Wiley Blackwell (American Society Bone & Mineral Research)",
number = "5",

}

Factors associated with feelings of loss of masculinity in men with prostate cancer in the RADAR trial. / Sharpley, Christopher F.; Bitsika, Vicki; Denham, James W.

In: Psycho-Oncology, Vol. 23, No. 5, 2014, p. 524-530.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Factors associated with feelings of loss of masculinity in men with prostate cancer in the RADAR trial

AU - Sharpley, Christopher F.

AU - Bitsika, Vicki

AU - Denham, James W.

PY - 2014

Y1 - 2014

N2 - Objectives To identify the factors underlying prostate cancer (PCa) patients' depression-anxiety, sexual problems, urinary dysfunction and androgen deprivation therapy (ADT)-linked breast changes and hot flushes, and test these as predictors of loss of masculinity (LoM) over 36months following diagnosis. Methods One thousand seventy patients from the TROG 03.04 (RADAR) trial the EORTC QLQ C-30 and PR 25 questionnaires, and the International Prostate Cancer Symptom Score of the American Urological Association at baseline, 3, 7, 12, 18, 24 and 36months. Selected items from these scales were factor-analysed to identify a four-component solution for responses at 18 and 36months, and these components were regressed against a single-item measuring LoM. Results Depression-anxiety factor was the most powerful predictor of LoM at both time points, followed by sexual problems of ADT side effects (breast changes and hot flushes). Urinary dysfunction was not a consistent predictor of LoM. Depression-anxiety was also the most significant factor distinguishing between those men who reported LoM and those who did not. Conclusions Although LoM is often reported as arising from ADT, the relative power of depression-anxiety in predicting LoM, both at the selected time points and using a time-lagged analysis, plus the finding that depression-anxiety was the most consistent difference between men who reported LoM and those who did not, argues for the presence of adverse mood states as being the key ingredient in deciding if PCa patients experience loss of their feelings of masculinity.

AB - Objectives To identify the factors underlying prostate cancer (PCa) patients' depression-anxiety, sexual problems, urinary dysfunction and androgen deprivation therapy (ADT)-linked breast changes and hot flushes, and test these as predictors of loss of masculinity (LoM) over 36months following diagnosis. Methods One thousand seventy patients from the TROG 03.04 (RADAR) trial the EORTC QLQ C-30 and PR 25 questionnaires, and the International Prostate Cancer Symptom Score of the American Urological Association at baseline, 3, 7, 12, 18, 24 and 36months. Selected items from these scales were factor-analysed to identify a four-component solution for responses at 18 and 36months, and these components were regressed against a single-item measuring LoM. Results Depression-anxiety factor was the most powerful predictor of LoM at both time points, followed by sexual problems of ADT side effects (breast changes and hot flushes). Urinary dysfunction was not a consistent predictor of LoM. Depression-anxiety was also the most significant factor distinguishing between those men who reported LoM and those who did not. Conclusions Although LoM is often reported as arising from ADT, the relative power of depression-anxiety in predicting LoM, both at the selected time points and using a time-lagged analysis, plus the finding that depression-anxiety was the most consistent difference between men who reported LoM and those who did not, argues for the presence of adverse mood states as being the key ingredient in deciding if PCa patients experience loss of their feelings of masculinity.

UR - http://www.scopus.com/inward/record.url?scp=84897999479&partnerID=8YFLogxK

U2 - 10.1002/pon.3448

DO - 10.1002/pon.3448

M3 - Article

VL - 23

SP - 524

EP - 530

JO - Psycho-Oncology

JF - Psycho-Oncology

SN - 1057-9249

IS - 5

ER -